Selective aldosterone blockade with eplerenone in patients with congestive heart failure
Selective aldosterone blockade with eplerenone in patients with congestive heart failure
复制标题
DOI：
10.1517/13543784.12.8.1423
复制
发表时间：
2003-08
影响因子：
6.1
通讯作者：
A. Salam
中科院分区：
文献类型：
--
作者：
A. Salam
在依普利酮急性心肌梗死后心力衰竭疗效和生存研究（EPHESUS）中，研究了依普利酮选择性醛固酮阻滞对急性心肌梗死后左心室功能下降的患者心血管死亡率和发病率的影响。这项具有里程碑意义的研究数据表明，依普利酮可以有效地补充充血性心力衰竭患者的治疗，并且与螺内酯相比副作用较少。关于这种新药在充血性心力衰竭以外的疾病状态中的可能益处，需要进一步研究，其中激活的肾素-血管紧张素-醛固酮系统系统已被牵连。
In the Eplerenone Postacute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) the effects of selective aldosterone blockade with eplerenone on cardiovascular mortality and morbidity were studied in patients with reduced left ventricular function postacute myocardial infarction. Data from this landmark study suggest that eplerenone can be an effective addition to the therapy of patients with congestive heart failure and is associated with fewer side effects than spironolactone. Further research is warranted concerning the possible benefits of this new agent in disease states other than congestive heart failure in which an activated renin-angiotensin-aldosterone system system has been implicated.